文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

MLH1启动子高甲基化对接受辅助放疗的I-II期子宫内膜癌的预后影响:多中心回顾性研究

The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated With Adjuvant Radiation Therapy: A Multi-Institutional Retrospective Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-05-14

该多中心回顾性研究纳入814例已知错配修复状态的I-II期子宫内膜样腺癌患者,评估MLH1启动子高甲基化(MLH1ph)对辅助放疗后预后及复发模式的影响。

要点

  • MLH1ph患者阴道复发(5% vs 0% vs 2%)和盆腔复发(5.3% vs 3.2% vs 0.5%)比例显著高于sdMMR和pMMR。
  • 肿瘤≥3.8cm、MMR缺陷、EBRT±VBT均与RFS降低独立相关。

核心结论

  • MLH1ph患者RFS较sdMMR和pMMR患者更差,部分归因于较高的局部区域复发比例。

研究设计与样本

  • 多中心回顾性队列研究,纳入814例I-II期子宫内膜样腺癌且已知MMR状态的患者。
  • MLH1启动子表观遗传沉默定义为MLH1ph,MSH2/MSH6/MLH1/PMS2突变定义为sdMMR。
  • 采用Kaplan-Meier法计算RFS,Cox比例风险模型进行单因素和多因素分析,SPSS 27软件统计。

主要发现

  • 中位诊断年龄65岁(IQR 58-71),59.2%为2-3级,56.0%肌层浸润≥50%,58%无淋巴血管间隙浸润。
  • 643例(78.1%)接受阴道近距离放疗,180例(21.9%)接受外照射(EBRT)±阴道近距离放疗(VBT)。
  • MMR proficient 550例(67.6%),deficient 264例(32.4%);dMMR中MLH1ph 171例(66%),sdMMR 93例(35.2%)。

关键数值与推荐

  • MLH1ph定义为MLH1启动子表观遗传沉默;sdMMR定义为MSH2、MSH6、MLH1或PMS2突变。
  • RFS采用Kaplan-Meier法计算,单因素和多因素分析采用Cox比例风险模型。

临床怎么用

  • 对I-II期子宫内膜样腺癌接受辅助放疗者,应明确MMR状态并区分MLH1ph与sdMMR以评估复发风险。
  • MLH1ph患者局部区域复发风险较高,或需加强阴道和盆腔监测及个体化放疗策略。

局限性

  • 回顾性多中心设计,可能存在选择偏倚和信息偏倚。
  • MLH1ph与sdMMR的复发模式差异样本量有限,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the impact of MLH1 promoter hypermethylation (MLH1ph) on prognosis and define the patterns of recurrence in stage I or II endometroid endometrial cancer (EEC) treated with adjuvant radiation therapy. METHODS AND MATERIALS: In a retrospective, institutional review board-approved, multi-institutional cohort study, 814 patients with stage I or II EEC with known mismatch repair (MMR) status were included. Tumors with MSH2, MSH6, MLH1, or PMS2 mutations were classified as somatic deficient MMR (sdMMR), whereas tumors with epigenetic silencing of the MLH1 promoter were classified as MLH1ph. Recurrence-free survival (RFS) was calculated by the Kaplan-Meier method. Univariate and multivariate analyses (UVA/MVA) were performed via Cox proportional hazards. Statistical analyses were conducted using SPSS version 27. RESULTS: The median age at diagnosis was 65 years (IQR, 58-71), and most patients had grade 2 or 3 disease (59.2%), ≥50% myometrial invasion (56.0%), and absence of lymphovascular space invasion (58%). Vaginal brachytherapy was delivered to 643 (78.1%) patients, and 180 (21.9%) patients received external beam radiation (EBRT) ± vaginal brachytherapy (VBT). MMR was proficient in 550 (67.6%) patients and deficient in 264 (32.4%) patients. Of the patients with dMMR, most patients harbored MLH1ph (n = 171, 66%), and 93 patients (35.2%) had somatic dMMR. Tumor size ≥ 3.8 cm [hazard ratio (HR), 2.2; P = .003], MMR deficient versus proficient (HR, 2.7; P < .001), and EBRT ± VBT versus VBT alone (HR, 1.9; P = .032) were associated with decreased RFS on MVA. On subgroup analysis including patients with dMMR only, patients with MLH1ph had worse RFS compared with patients with sdMMR (HR, 1.9; 95% CI, 1.1-3.6; P = .025). Distant recurrence was the most common recurrence site, regardless of MMR status. Patients with MLH1ph had significantly higher proportion of vaginal (5% vs 0% vs 2%) and pelvic (5.3% vs 3.2% vs 0.5%) recurrences compared with sdMMR and pMMR, respectively (P = .038). CONCLUSIONS: Patients with MLH1ph had worse RFS, which may be attributed in part to a higher proportion of locoregional recurrences compared with the pMMR and sdMMR patients.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sherwani ZK, Damast S, Fields EC, et al. The Prognostic Impact of MLH1 Promoter Hypermethylation in Stage I-II Endometrial Cancer Treated With Adjuvant Radiation Therapy: A Multi-Institutional Retrospective Study. Int J Radiat Oncol Biol Phys. 2025. PMID: 40379143. doi:10.1016/j.ijrobp.2025.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。